OS Therapies Inc. Advances Toward Potential 2026 Osteosarcoma Treatment Launch with FDA RMAT Designation and Strong Clinical Data
OS Therapies Inc. achieves critical regulatory milestones including FDA RMAT designation and BLA preparation for OST-HER2, demonstrating statistically significant efficacy in osteosarcoma patients with potential U.S. launch in 2026.
Read the full story